SEC Form 4 · accession 0001104659-19-011559
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Gregory S Patrick
Officer — Sr VP, Chief Financial Officer
Period of report
Feb 27, 2019
Accepted (ET)
Feb 28, 2019 · 4:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 27, 2019 | M | 20,000 | $9.13 | A | 67,896 | D | |
| Common StockF2 | Feb 27, 2019 | S | 20,000 | $41.5325 | D | 47,896 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $9.13 | Feb 27, 2019 | M | 20,000 | D | — | Mar 3, 2025 | Common Stock | 20,000 | 15,000 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted November 28, 2018.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.0000 to $42.1900, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The option vests in four equal annual installments beginning on March 3, 2016.